Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
The Pharma Data
JULY 27, 2021
Each of these three investigational therapies uses a different approach to treat a highly prevalent disease for which new treatment options are very much needed. TNB-585 complements Amgen’s existing prostate cancer portfolio, which includes acapatamab (formerly AMG 160) and AMG 509, both in Phase 1. ” In June 2021, AbbVie Inc.
52 
Let's personalize your content